IDEAYA Biosciences, Inc. (IDYA) Company Overview

IDEAYA Biosciences, Inc. is a Nasdaq-listed precision oncology company developing targeted cancer medicines for molecularly defined patient groups. Its official company description emphasizes the combination of small-molecule discovery, structural biology, bioinformatics, and translational biomarkers. In plain English, IDEAYA tries to find a tumor dependency, identify the patients whose cancers rely on that dependency, and design a drug or drug combination that exploits it.

Why does the company matter in precision oncology?

The company matters because it has moved beyond a broad discovery platform into late-stage development. Darovasertib, its lead program, produced positive registrational data in metastatic uveal melanoma and is moving toward IDEAYA's first new drug application. At the same time, the company is building a second growth pillar around antibody-drug conjugates, especially IDE849 in DLL3-positive tumors, and retaining earlier programs in synthetic lethality and the MTAP pathway. That mix gives IDEAYA more than one scientific route to value creation, but it also creates a difficult resource-allocation problem: management must fund a potential launch while advancing multiple expensive clinical programs.

How is IDEAYA organized?

IDEAYA reports one operating segment, but the portfolio has four engines: darovasertib; ADC and DNA-damage-response combinations; MTAP-deleted cancer programs; and next-generation therapies. Long-lived assets are primarily in the United States, while trials and partnerships are global. Value depends on data, approvals, manufacturing readiness, and partner execution.

IDEAYA has not generated product-sales revenue. Its reported revenue comes from collaborations, licenses, development services, and milestone economics. The most important current agreement is the 2025 Servier transaction for darovasertib outside the United States. IDEAYA received a $210.0 million upfront payment, can earn up to $320.0 million in additional milestones, receives development cost sharing or reimbursement, and is eligible for mid-teen to low-twenties royalties on ex-U.S. sales. IDEAYA retained U.S. rights, so it preserves the highest-upside commercial territory while outsourcing much of the international commercial build.

Which revenue stream is economically most important?

In 2025, IDEAYA recorded $218.7 million of collaboration revenue, largely from Servier, but that was transaction-driven rather than recurring demand. The durable potential economics are U.S. darovasertib sales, ex-U.S. royalties, milestones, and later pipeline sales or royalties. Upfront cash improves liquidity without proving approval or adoption.

What are the key partnership trade-offs?

The nine candidates are not equally valuable. Darovasertib carries the largest near-term weight. IDE849 is the most visible second platform, while IDE034, IDE161, IDE397, IDE892, IDE574, and IDE275 remain earlier and need more evidence before supporting durable cash-flow forecasts.

How broad is the darovasertib opportunity?

IDEAYA is testing darovasertib across the disease course. OptimUM-02 addresses first-line HLA-A2-negative metastatic uveal melanoma. OptimUM-01 has enrolled about 100 HLA-A2-positive metastatic patients. OptimUM-10 is a roughly 450-patient neoadjuvant Phase 3 study designed around eye preservation and vision outcomes, while OptimUM-11 is planned as a roughly 450-patient adjuvant Phase 3 trial focused on relapse-free survival. This lifecycle strategy is important: one molecule could potentially serve metastatic patients, patients at risk of losing an eye, and patients at high risk of later metastasis.

What should researchers track beyond the lead asset?

IDEAYA's defining events changed approval probability, financing needs, or pipeline breadth.

Seven decisions that still influence the company

1. 2018
   IDEAYA licensed the PKC inhibitor now called darovasertib from Novartis. That transaction supplied the asset that became the company's lead commercial opportunity.
2. 2019
   The May initial public offering created a public-equity funding channel and established IDYA on the Nasdaq Global Select Market.
3. 2020
   The GSK collaboration validated IDEAYA's synthetic-lethality platform and brought external capital, but later termination showed that partner priorities can change.
4. 2022
   A Pfizer clinical collaboration supported darovasertib plus crizotinib, turning a targeted molecule into the combination used in the registrational metastatic trial.
5. 2024
   The Hengrui license added IDE849 and moved IDEAYA into DLL3-targeted antibody-drug conjugates, broadening the company beyond small molecules.
6. 2025
   The Servier agreement monetized ex-U.S. darovasertib rights for $210.0M upfront while preserving U.S. economics and helping fund multiple Phase 3 programs.
7. 2026
   Positive OptimUM-02 data and FDA Real-Time Oncology Review moved IDEAYA from a platform story toward a potential launch story; the March GSK exit also forced tighter portfolio prioritization.

IDEAYA selectively licenses assets and partners programs while retaining meaningful rights. This can improve capital efficiency, but it creates complex milestone, supply, and counterparty obligations.

The latest official period is the quarter ended March 31, 2026. IDEAYA's Q1 2026 Form 10-Q shows ample liquidity and rising development spending. The central question is whether that spending converts into submissions, successful trials, and launch readiness.

How did Q1 2026 compare with prior periods?

What does the 2025 annual baseline add?

The 2025 annual report recorded $218.7 million of collaboration revenue, $314.7 million of R&D, $63.3 million of G&A, and a $113.7 million net loss. The revenue jump from $7.0 million in 2024 reflected Servier accounting, not recurring product demand.

Darovasertib has the clearest path from clinical evidence to revenue. In the 313-patient OptimUM-02 study, patients were randomized 2:1 to darovasertib plus crizotinib or investigator's choice of checkpoint therapy. According to the company's June 2026 ASCO data release, blinded independent review showed median progression-free survival of 6.9 months versus 3.1 months, a hazard ratio of 0.42, and a p-value below 0.0001.

How large was the clinical separation?

What remains unresolved before commercialization?

Overall-survival data were immature at the January 2026 cutoff, while the combination's safety profile was described as manageable. The NDA is targeted for H2 2026; labeling, manufacturing, reimbursement, and launch remain separate hurdles.

Liquidity is IDEAYA's clearest financial strength. At March 31, 2026, cash, cash equivalents, and marketable securities totaled $972.9 million. Management's Q1 2026 business update maintained runway guidance into 2030. Total liabilities were $93.1 million, and the filing did not disclose funded term debt.

Where is the R&D budget going?

How capital intensive is the model?

IDEAYA has one class of common stock and no founder-controlled dual-class structure. Ownership is institutionally concentrated, while insiders hold a meaningful but non-controlling stake. The 2026 proxy statement reported 87,856,154 shares outstanding at March 31, 2026. Four institutions each exceeded 5% in the proxy, and current directors and executive officers as a group beneficially owned 4.7%, including options exercisable within 60 days.

What does the ownership structure signal?

All directors other than CEO Yujiro Hata were deemed independent, and the board chair is separate. The main governance issue is dilution rather than control. Q1 2026 stock-based compensation was $14.5 million, and 14.8 million options were excluded from diluted EPS as anti-dilutive. Equity aids retention but creates a future claim on per-share value.

IDEAYA competes at disease and technology levels. Kimmtrak is approved for HLA-A2-positive metastatic uveal melanoma, while IDEAYA initially targets HLA-A2-negative disease. Rivals pursue T-cell therapies, local ocular treatments, ADCs, bispecifics, and radiopharmaceuticals. A first-in-class label is not a moat without efficacy, safety, manufacturing, and patient access.

Where could IDEAYA have a durable advantage?

The potential moat is the integrated link among target biology, biomarkers, chemistry, and trial design. Darovasertib is the first proof point; IDE849 and the MTAP portfolio must show repeatability.

The largest opportunity is regulatory conversion: completing the darovasertib NDA in the second half of 2026 and obtaining a commercially usable label. The second is lifecycle expansion. Approximately 100 HLA-A2-positive metastatic patients have been enrolled in OptimUM-01, while two roughly 450-patient Phase 3 programs address neoadjuvant and adjuvant disease. A broader label could transform darovasertib from a narrow rare-cancer product into a multi-setting uveal-melanoma franchise.

Which milestones matter most next?

Partnerships can supply combination drugs, share trial costs, and add commercial reach, but the highest-quality opportunity is clinical evidence that improves the probability and breadth of future cash flows.

IDEAYA's 2025 Form 10-K risk factors begin with the core issue: the company has no approved products, has accumulated substantial losses, and depends on successful development, approval, and commercialization. Positive Phase 2/3 data reduce one type of risk but do not eliminate regulatory, manufacturing, launch, reimbursement, or long-term safety risk.

Which risks are financially material?

Liquidity buys time, not efficacy or demand. Conversely, a net loss can be value-creating when spending advances a high-information milestone. The key test is whether incremental cash burn improves approval probability, commercial readiness, or diversification.

Because IDEAYA is pre-product-revenue, a conventional consolidated DCF is unstable. A better framework is probability-adjusted and asset-by-asset, using eligible patients, biomarker rates, penetration, net price, treatment duration, rights economics, launch timing, costs, and technical and regulatory probabilities.

Which variables drive intrinsic value most?

Cash adds to enterprise value, but future burn must be deducted. Collaboration revenue should follow contracts, not a 2025 extrapolation. Terminal value should reflect patent life and competition. A base case may include darovasertib with limited pipeline value; upside can add broader labels and IDE849; downside can delay approval, reduce penetration, and require financing.

IDEAYA has crossed an important threshold. It remains a loss-making clinical-stage biotechnology company, but positive randomized darovasertib data, a planned 2026 NDA, a nearly $1.0 billion liquidity position, and an increasingly broad pipeline make it more than an early research platform. The strongest part of the story is the combination of differentiated lead-asset evidence and the financial capacity to pursue approval, lifecycle expansion, and second-franchise candidates.

The main weakness is concentration. Darovasertib carries much of the near-term value, and commercialization introduces capabilities that IDEAYA has not yet demonstrated at scale. The pipeline is scientifically broad but expensive, partner-dependent, and mostly early. Students and investors should therefore monitor four linked tests: whether the NDA progresses on schedule, whether survival and safety remain supportive, whether IDE849 or another program becomes a credible second pillar, and whether cash burn converts into regulatory and commercial milestones faster than dilution expands.